Helus Pharma Inc. (HELP)

$7.73 -1.24 (-13.82%)
Market Cap N/A
Revenue (ttm) N/A
Net Income (ttm) N/A
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin N/A
Debt to Equity Ratio N/A
Volume 864,772
Avg Vol N/A
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K N/A
Beta N/A
Analysts N/A
Price Target N/A
everup
everup Feb. 4 at 4:15 PM
$HELP suck a phat one lol
0 · Reply
BelieveinthePK
BelieveinthePK Feb. 4 at 3:52 AM
$HELP does anybody have a bead on insider trading activity?
0 · Reply
HughJasol
HughJasol Feb. 3 at 4:14 PM
$HELP gar… bage… this will do nothing but kill all the bag holders accounts…
0 · Reply
Morgan8758
Morgan8758 Feb. 3 at 2:04 PM
$HELP when is the results going to be published? this thing just keeps hovering around the same price forever
2 · Reply
cambruck7
cambruck7 Feb. 2 at 9:03 PM
$HELP
0 · Reply
Horseman23
Horseman23 Feb. 2 at 7:21 PM
$HELP
0 · Reply
Rocketzz
Rocketzz Feb. 2 at 7:17 PM
$HELP how much cash on hand? Any open atm’s or other dilution in near term?
1 · Reply
explover
explover Feb. 2 at 7:01 PM
$HELP the ship has sailed, also to fix a typo - not RA Capital, but rather Orbimed
0 · Reply
Mastacash
Mastacash Feb. 2 at 5:44 PM
$HELP anybody still here? Nothing has changed for the company. Except now further undervalued and closer to dat release.
1 · Reply
Where_is_my_lambo
Where_is_my_lambo Feb. 2 at 4:12 PM
$HELP your chart is tough to see and read. Perhaps this makes it clearer, what a shit stock this continues to be.
0 · Reply
Latest News on HELP
Cybin Initiates At-The-Market Equity Program of up to US$100 Million

Dec 30, 2025, 3:33 PM EST - 5 weeks ago

Cybin Initiates At-The-Market Equity Program of up to US$100 Million

Cybin to Transfer U.S. Stock Exchange Listing to Nasdaq

Dec 18, 2025, 12:29 PM EST - 6 weeks ago

Cybin to Transfer U.S. Stock Exchange Listing to Nasdaq

Cybin Inc. (CYBN) Q2 2026 Earnings Call Transcript

Nov 13, 2025, 3:11 PM EST - 2 months ago

Cybin Inc. (CYBN) Q2 2026 Earnings Call Transcript

Cybin Reports Second Quarter Fiscal Year 2026 Financial Results and Recent Business Highlights

Nov 13, 2025, 7:20 AM EST - 2 months ago

Cybin Reports Second Quarter Fiscal Year 2026 Financial Results and Recent Business Highlights

Cybin to Participate in the Jefferies Global Healthcare Conference in London

Nov 12, 2025, 7:30 AM EST - 3 months ago

Cybin to Participate in the Jefferies Global Healthcare Conference in London

Cybin to Announce Second Quarter Financial Results and Provide Business Update on November 13, 2025

Nov 6, 2025, 7:30 AM EST - 3 months ago

Cybin to Announce Second Quarter Financial Results and Provide Business Update on November 13, 2025

Cybin to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference

Nov 5, 2025, 7:30 AM EST - 3 months ago

Cybin to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference

Cybin to Participate at the 2025 Milken Institute Future of Health Summit

Nov 3, 2025, 7:30 AM EST - 3 months ago

Cybin to Participate at the 2025 Milken Institute Future of Health Summit

Cybin Announces Closing of $175 Million Registered Direct Offering

Oct 31, 2025, 4:19 PM EDT - 3 months ago

Cybin Announces Closing of $175 Million Registered Direct Offering

Cybin Announces $175 Million Registered Direct Offering

Oct 28, 2025, 8:00 AM EDT - 3 months ago

Cybin Announces $175 Million Registered Direct Offering

BetterLife Pharma Appoints Doug Drysdale as Corporate Advisor

Oct 21, 2025, 8:00 AM EDT - 3 months ago

BetterLife Pharma Appoints Doug Drysdale as Corporate Advisor

Cybin Highlights Neuropsychiatry Platform and Upcoming Clinical Milestones

Sep 23, 2025, 5:00 PM EDT - 4 months ago

Cybin Highlights Neuropsychiatry Platform and Upcoming Clinical Milestones

CYBN Investors Have Opportunity to Join Cybin Inc. Fraud Investigation with the Schall Law Firm

Sep 11, 2025, 3:59 PM EDT - 5 months ago

CYBN Investors Have Opportunity to Join Cybin Inc. Fraud Investigation with the Schall Law Firm

Cybin to Participate in TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit

Sep 11, 2025, 7:30 AM EDT - 5 months ago

Cybin to Participate in TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit

Cybin Completes Enrollment in Phase 2 Study Evaluating CYB004 for the Treatment of Generalized Anxiety Disorder

Sep 8, 2025, 7:30 AM EDT - 5 months ago

Cybin Completes Enrollment in Phase 2 Study Evaluating CYB004 for the Treatment of Generalized Anxiety Disorder

Cybin to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Sep 4, 2025, 7:30 AM EDT - 5 months ago

Cybin to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Cybin to Participate in the Cantor Global Healthcare Conference 2025

Sep 3, 2025, 7:30 AM EDT - 5 months ago

Cybin to Participate in the Cantor Global Healthcare Conference 2025

Cybin Announces Senior Leadership Changes

Sep 2, 2025, 7:30 AM EDT - 5 months ago

Cybin Announces Senior Leadership Changes

Cybin Receives Australian Approval for EMBRACE, a Multinational Pivotal Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

Aug 26, 2025, 7:30 AM EDT - 5 months ago

Cybin Receives Australian Approval for EMBRACE, a Multinational Pivotal Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

Cybin Announces Results of Annual Meeting of Shareholders

Aug 18, 2025, 5:30 PM EDT - 6 months ago

Cybin Announces Results of Annual Meeting of Shareholders

Cybin Reports Important Progress on Key Milestones and First Quarter Fiscal Year 2026 Financial Results

Aug 13, 2025, 5:30 PM EDT - 6 months ago

Cybin Reports Important Progress on Key Milestones and First Quarter Fiscal Year 2026 Financial Results

Cybin Receives European Approval for EMBRACE, a Multinational Phase 3 Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

Aug 7, 2025, 7:30 AM EDT - 6 months ago

Cybin Receives European Approval for EMBRACE, a Multinational Phase 3 Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

Cybin to Participate in the Canaccord Genuity 45th Annual Growth Conference

Aug 6, 2025, 7:30 AM EDT - 6 months ago

Cybin to Participate in the Canaccord Genuity 45th Annual Growth Conference

Cybin Receives UK MHRA Approval to Commence EMBRACE, A Multinational Pivotal Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

Jul 17, 2025, 7:30 AM EDT - 7 months ago

Cybin Receives UK MHRA Approval to Commence EMBRACE, A Multinational Pivotal Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

REPEAT/Cybin Announces Financing of up to US$500 Million Aggregate Principal Amount of Convertible Debentures

Jul 1, 2025, 11:19 AM EDT - 7 months ago

REPEAT/Cybin Announces Financing of up to US$500 Million Aggregate Principal Amount of Convertible Debentures

Cybin Reports Fiscal Year 2025 Financial Results and Recent Business Highlights

Jun 30, 2025, 10:03 PM EDT - 7 months ago

Cybin Reports Fiscal Year 2025 Financial Results and Recent Business Highlights

Cybin Announces Financing of up to US$500 Million Aggregate Principal Amount of Convertible Debentures

Jun 30, 2025, 9:27 PM EDT - 7 months ago

Cybin Announces Financing of up to US$500 Million Aggregate Principal Amount of Convertible Debentures

Cybin Provides Corporate Update and Highlights Positive Regulatory Signals for Psychedelic Therapeutics

Jun 13, 2025, 7:45 AM EDT - 8 months ago

Cybin Provides Corporate Update and Highlights Positive Regulatory Signals for Psychedelic Therapeutics

Cybin to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Conference

Jun 12, 2025, 7:30 AM EDT - 8 months ago

Cybin to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Conference

Cybin to Participate in the 2025 Psychedelic Science Conference

Jun 11, 2025, 7:30 AM EDT - 8 months ago

Cybin to Participate in the 2025 Psychedelic Science Conference

Cybin Announces Additional U.S. Patent Supporting its CYB004 Program in Phase 2 Development for Generalized Anxiety Disorder

Jun 3, 2025, 7:30 AM EDT - 8 months ago

Cybin Announces Additional U.S. Patent Supporting its CYB004 Program in Phase 2 Development for Generalized Anxiety Disorder

Cybin to Participate in Water Tower Research Fireside Chat on May 29, 2025

May 22, 2025, 7:30 AM EDT - 9 months ago

Cybin to Participate in Water Tower Research Fireside Chat on May 29, 2025

Cybin Applauds FDA Commissioner Dr. Martin Makary's Call to Accelerate and Prioritize Research on Psychedelic Therapeutics

May 20, 2025, 7:30 AM EDT - 9 months ago

Cybin Applauds FDA Commissioner Dr. Martin Makary's Call to Accelerate and Prioritize Research on Psychedelic Therapeutics

Cybin Engages Thermo Fisher Scientific to Provide U.S.-Based Manufacturing for its CYB003 Program for the Adjunctive Treatment of Major Depressive Disorder

May 15, 2025, 7:30 AM EDT - 9 months ago

Cybin Engages Thermo Fisher Scientific to Provide U.S.-Based Manufacturing for its CYB003 Program for the Adjunctive Treatment of Major Depressive Disorder

Cybin to Participate in the Alliance Global Partners Healthcare Company Showcase

May 14, 2025, 7:30 AM EDT - 9 months ago

Cybin to Participate in the Alliance Global Partners Healthcare Company Showcase

Cybin Announces Additional U.S. Patent Supporting its CYB003 Breakthrough Therapy Program in Phase 3 Development for Major Depressive Disorder

May 8, 2025, 7:30 AM EDT - 9 months ago

Cybin Announces Additional U.S. Patent Supporting its CYB003 Breakthrough Therapy Program in Phase 3 Development for Major Depressive Disorder

Cybin to Participate at the 28th Annual Milken Institute Global Conference

May 1, 2025, 7:30 AM EDT - 9 months ago

Cybin to Participate at the 28th Annual Milken Institute Global Conference

Cybin Announces Additional Strategic Clinical Site Partnerships to Support PARADIGM, a Multinational Phase 3 Program Evaluating CYB003

Apr 23, 2025, 7:30 AM EDT - 10 months ago

Cybin Announces Additional Strategic Clinical Site Partnerships to Support PARADIGM, a Multinational Phase 3 Program Evaluating CYB003

Cybin Partners with Osmind to Accelerate Commercial Preparation for its Clinical-Stage Psychiatry Programs

Apr 21, 2025, 8:00 AM EDT - 10 months ago

Cybin Partners with Osmind to Accelerate Commercial Preparation for its Clinical-Stage Psychiatry Programs

Cybin Reports Third Quarter Fiscal Year 2025 Financial Results and Recent Business Highlights

Feb 10, 2025, 9:48 PM EST - 1 year ago

Cybin Reports Third Quarter Fiscal Year 2025 Financial Results and Recent Business Highlights

Cybin Launches Strategic Clinical Site Partnerships to Support PARADIGM, a Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

Jan 15, 2025, 12:07 PM EST - 1 year ago

Cybin Launches Strategic Clinical Site Partnerships to Support PARADIGM, a Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

Cybin Highlights 2024 Accomplishments and Upcoming Milestones for 2025

Jan 13, 2025, 7:30 AM EST - 1 year ago

Cybin Highlights 2024 Accomplishments and Upcoming Milestones for 2025

Cybin to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025

Jan 9, 2025, 5:00 PM EST - 1 year ago

Cybin to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025

Cybin Announces Poster Presentations at the 2024 American College of Neuropsychopharmacology Annual Meeting, Including CYB003 12-Month Efficacy Results

Dec 10, 2024, 7:30 AM EST - 1 year ago

Cybin Announces Poster Presentations at the 2024 American College of Neuropsychopharmacology Annual Meeting, Including CYB003 12-Month Efficacy Results

Cybin to Participate in Water Tower Research Fireside Chat on December 11, 2024

Dec 4, 2024, 7:30 AM EST - 1 year ago

Cybin to Participate in Water Tower Research Fireside Chat on December 11, 2024

Cybin Reports Positive Phase 2 Data for CYB003, Demonstrating Breakthrough 12-Month Efficacy in Treating Major Depressive Disorder

Nov 18, 2024, 7:00 AM EST - 1 year ago

Cybin Reports Positive Phase 2 Data for CYB003, Demonstrating Breakthrough 12-Month Efficacy in Treating Major Depressive Disorder

Cybin to Present 12-Month Phase 2 Data for CYB003 in Major Depressive Disorder on November 18, 2024

Nov 14, 2024, 7:30 AM EST - 1 year ago

Cybin to Present 12-Month Phase 2 Data for CYB003 in Major Depressive Disorder on November 18, 2024

everup
everup Feb. 4 at 4:15 PM
$HELP suck a phat one lol
0 · Reply
BelieveinthePK
BelieveinthePK Feb. 4 at 3:52 AM
$HELP does anybody have a bead on insider trading activity?
0 · Reply
HughJasol
HughJasol Feb. 3 at 4:14 PM
$HELP gar… bage… this will do nothing but kill all the bag holders accounts…
0 · Reply
Morgan8758
Morgan8758 Feb. 3 at 2:04 PM
$HELP when is the results going to be published? this thing just keeps hovering around the same price forever
2 · Reply
cambruck7
cambruck7 Feb. 2 at 9:03 PM
$HELP
0 · Reply
Horseman23
Horseman23 Feb. 2 at 7:21 PM
$HELP
0 · Reply
Rocketzz
Rocketzz Feb. 2 at 7:17 PM
$HELP how much cash on hand? Any open atm’s or other dilution in near term?
1 · Reply
explover
explover Feb. 2 at 7:01 PM
$HELP the ship has sailed, also to fix a typo - not RA Capital, but rather Orbimed
0 · Reply
Mastacash
Mastacash Feb. 2 at 5:44 PM
$HELP anybody still here? Nothing has changed for the company. Except now further undervalued and closer to dat release.
1 · Reply
Where_is_my_lambo
Where_is_my_lambo Feb. 2 at 4:12 PM
$HELP your chart is tough to see and read. Perhaps this makes it clearer, what a shit stock this continues to be.
0 · Reply
ChristopherMcC
ChristopherMcC Feb. 2 at 3:59 PM
$HELP to add, I believe some of the ATAI investments in programs have downright failed in Recognify...
0 · Reply
ChristopherMcC
ChristopherMcC Feb. 2 at 3:57 PM
$HELP it should also be noted that the other firms have faced significantly more headwind than Helus in their trials, with GHRS having to resubmit something to do with the mice, and Compass having to reprogram their clinical trials. I believe MindMed also had a CEO / major ownership squabble and some sortve trial complication as well. .... and yet...
0 · Reply
ChristopherMcC
ChristopherMcC Feb. 2 at 3:53 PM
$HELP heres a look of the performance of "Helus". The comparisons are the other major psych developers. There is very little different about the firms beyond capital management in their approach to commercialization, with the exception of Atai, which acts as a holding company that invests in multiple programs, such as Comp360 (compass) etc. The major difference between these firms is capital management, excessive and poorly executed dilution, and investor confidence.
0 · Reply
everup
everup Feb. 2 at 2:51 PM
$HELP go to hell
0 · Reply
firetypecracker
firetypecracker Feb. 2 at 1:50 PM
$HELP Helus Pharma initiated with a Buy at Jefferies Jefferies analyst Andrew Tsai initiated coverage of Helus Pharma () with a Buy rating and $22 The firm sees the stock potentially moving “significantly higher” into three catalysts in 2026. Helus’ lead asset, HLP003, has a 60% probability of success in a Phase III trial for adjunctive major depressive disorder, which could result in a 100%-200% share rally, the analyst tells investors in a research note. Jefferies adds that HLP004 is a short-duration psychedelic that has “de-risking” Phase II data in Q1. It also believes Helus's finding a CEO is another catalyst. https://www.tipranks.com/news/the-fly/helus-pharma-initiated-with-a-buy-at-jefferies-thefly
0 · Reply
kev90123
kev90123 Feb. 2 at 12:04 AM
$HELP
0 · Reply
Ridethesqueeze
Ridethesqueeze Feb. 1 at 11:56 PM
$HELP Andrew Tsai initiated coverage with a buy rating. | Helus Pharma initiated with a Buy at Jefferies | https://tipranks.onelink.me/WJho/l13xljq6
0 · Reply
BankOnTheFuture
BankOnTheFuture Feb. 1 at 5:50 PM
$CMPS $ATAI $HELP $DFTX Getting closer. https://www.news-medical.net/news/20260130/First-of-its-kind-clinical-guidance-on-psychedelic-medicine-released.aspx
0 · Reply
Alex1710
Alex1710 Feb. 1 at 2:09 PM
$HELP Management has a very disciplined approach, they don't try to skip any clinical step, very strong IP protection. Clinicals results so far has shown without a shadow of a doubt efficacy ans safety. Very very bullish. HLP003 (BTD) will reach the market, that's a no brainer.
1 · Reply
Xochi_Research_Group
Xochi_Research_Group Feb. 1 at 7:49 AM
$ASTS the supper bubble is already bursting. Many will be trapped. Don't say I didn't warn you. $ASTS $TMC $RKLB $HELP
6 · Reply
Rico_Again_Jorge
Rico_Again_Jorge Jan. 31 at 1:09 PM
$HELP I had to leave my kid at a Somalian daycare center to lear what is unfolding here. Scam here. Scam there. Quality scam
1 · Reply
kev90123
kev90123 Jan. 30 at 10:42 PM
$HELP
0 · Reply